Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States

IntroductionPerioperative (neoadjuvant and adjuvant) pembrolizumab has shown favorable efficacy in patients with early-stage non-small cell lung cancer (NSCLC). This study aims to evaluate the cost-effectiveness of this treatment from the perspective of the United States healthcare payers.MethodsWe...

Full description

Bibliographic Details
Main Authors: Wentao Tian, Lishui Niu, Ziqi Wang, Ruoyu Lu, Gang Xiao, Fuxing Deng, Guilong Tanzhu, Rongrong Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Immunology
Subjects:
neoadjuvant
adjuvant
pembrolizumab
cost-effectiveness
early-stage
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1268070/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1268070/full

Similar Items